Stifel Nicolaus Boosts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $25.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target hoisted by research analysts at Stifel Nicolaus from $24.00 to $25.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 0.16% from the company’s current price.

ACAD has been the subject of a number of other reports. Royal Bank Of Canada upped their price objective on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. HC Wainwright lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 30th. Canaccord Genuity Group increased their price target on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, June 29th. Finally, Bank of America lifted their target price on shares of ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Thirteen analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.17.

ACADIA Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ:ACAD opened at $24.96 on Tuesday. ACADIA Pharmaceuticals has a 52-week low of $19.69 and a 52-week high of $28.35. The stock has a market cap of $4.27 billion, a P/E ratio of 11.35, a price-to-earnings-growth ratio of 18.32 and a beta of 0.80. The business’s 50 day moving average is $23.10 and its 200 day moving average is $23.25.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The firm had revenue of $268.10 million for the quarter, compared to the consensus estimate of $280.25 million. During the same period in the previous year, the company posted $0.11 EPS. ACADIA Pharmaceuticals’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, sell-side analysts anticipate that ACADIA Pharmaceuticals will post 0.37 EPS for the current fiscal year.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,506 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the completion of the transaction, the executive vice president owned 66,145 shares of the company’s stock, valued at $1,441,299.55. This trade represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider James Kihara sold 5,401 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares of the company’s stock, valued at $519,100.62. The trade was a 18.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 10,239 shares of company stock valued at $219,813 over the last ninety days. Corporate insiders own 26.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ACAD. Handelsbanken Fonder AB increased its position in shares of ACADIA Pharmaceuticals by 11.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 63,133 shares of the biopharmaceutical company’s stock valued at $1,597,000 after purchasing an additional 6,400 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of ACADIA Pharmaceuticals by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 103,290 shares of the biopharmaceutical company’s stock worth $2,613,000 after purchasing an additional 2,561 shares during the period. Gradient Investments LLC lifted its stake in shares of ACADIA Pharmaceuticals by 13.3% in the 2nd quarter. Gradient Investments LLC now owns 32,738 shares of the biopharmaceutical company’s stock worth $828,000 after acquiring an additional 3,838 shares during the period. GAMMA Investing LLC boosted its stake in shares of ACADIA Pharmaceuticals by 15.6% in the second quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 402 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter worth $1,090,000. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.